Solid Biosciences Inc (SLDB) Expected to Announce Earnings of -$0.58 Per Share

Share on StockTwits

Wall Street analysts expect that Solid Biosciences Inc (NASDAQ:SLDB) will post earnings per share of ($0.58) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Solid Biosciences’ earnings, with the highest EPS estimate coming in at ($0.55) and the lowest estimate coming in at ($0.60). Solid Biosciences posted earnings of ($0.84) per share in the same quarter last year, which suggests a positive year over year growth rate of 31%. The company is scheduled to issue its next earnings report on Thursday, April 4th.

According to Zacks, analysts expect that Solid Biosciences will report full year earnings of ($2.21) per share for the current financial year, with EPS estimates ranging from ($2.26) to ($2.17). For the next financial year, analysts anticipate that the company will post earnings of ($2.54) per share, with EPS estimates ranging from ($2.93) to ($2.22). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Solid Biosciences.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.01.

A number of equities analysts have recently issued reports on SLDB shares. Zacks Investment Research raised Solid Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. Credit Suisse Group started coverage on Solid Biosciences in a research note on Thursday, September 6th. They set a “neutral” rating and a $38.00 target price for the company. Finally, Citigroup started coverage on Solid Biosciences in a research note on Tuesday, November 6th. They set a “sell” rating and a $25.00 target price for the company. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. Solid Biosciences presently has a consensus rating of “Hold” and a consensus target price of $42.56.

Shares of SLDB stock traded down $1.86 during trading hours on Wednesday, reaching $28.49. 201,766 shares of the company’s stock were exchanged, compared to its average volume of 271,214. The company has a market cap of $1.10 billion and a price-to-earnings ratio of -9.89. Solid Biosciences has a 1 year low of $6.83 and a 1 year high of $54.84.

In other Solid Biosciences news, CEO Ilan Ganot sold 50,000 shares of the stock in a transaction on Thursday, November 15th. The stock was sold at an average price of $30.84, for a total transaction of $1,542,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joel Solomon Zev Schneider sold 21,990 shares of the stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $30.84, for a total value of $678,171.60. The disclosure for this sale can be found here. Insiders sold a total of 130,240 shares of company stock valued at $4,033,763 over the last ninety days.

A number of large investors have recently made changes to their positions in SLDB. Boxer Capital LLC grew its holdings in Solid Biosciences by 270.7% during the 2nd quarter. Boxer Capital LLC now owns 2,780,000 shares of the company’s stock valued at $99,051,000 after buying an additional 2,030,000 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Solid Biosciences during the 3rd quarter valued at $24,288,000. Partner Fund Management L.P. acquired a new stake in Solid Biosciences during the 2nd quarter valued at $16,724,000. Vanguard Group Inc. grew its holdings in Solid Biosciences by 82.0% during the 3rd quarter. Vanguard Group Inc. now owns 675,180 shares of the company’s stock valued at $31,855,000 after buying an additional 304,286 shares during the last quarter. Finally, FMR LLC grew its holdings in Solid Biosciences by 424.4% during the 3rd quarter. FMR LLC now owns 317,997 shares of the company’s stock valued at $15,003,000 after buying an additional 257,354 shares during the last quarter. Hedge funds and other institutional investors own 63.59% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation.

See Also: What is the quiet period?

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply